Best Japanese Stocks To Invest In Right Now

Cloud content management company�Box is one of the most anticipated tech initial public offerings of this year. The company raised $100 million in a Series E funding on Dec. 2013, obtaining a valuation close to $2 billion. This late-stage capital is rumored to be led by a group of strategic Japanese investors who are willing to help the company expand its customer base in Asia.

According to Quartz, the cloud storage company may already have secretly filed paperwork for an initial public offering� in an attempt to start trading before its main competitor Dropbox, which may have reached�a $10 billion valuation according to�The Wall Street Journal.�Does Box have sufficient economic moat to continue growing in a fierce environment, where even giant competitors such as Amazon.com� (NASDAQ: AMZN  ) and Google (NASDAQ: GOOG  ) are struggling to capture market share?�

Source: Box Website

Best Japanese Stocks To Watch For 2015: Banco Bilbao Vizcaya Argentaria S.A. (BBVA)

Banco Bilbao Vizcaya Argentaria, S.A. (BBVA) is a diversified international financial group, with strengths in the traditional banking businesses of retail banking, asset management, private banking and wholesale banking. The Company also has investments in some of Spain�� companies. During the year ended December 31, 2009, BBVA focused its operations on six major business areas: Spain and Portugal, Wholesale Banking and Asset Management, Mexico, The United States, South America and Corporate Activities. On August 21, 2009, through its subsidiary BBVA Compass, BBVA acquired certain assets of Guaranty from the United States Federal Deposit Insurance Corporation (the FDIC).

Spain and Portugal

The Spain and Portugal business area focuses on providing banking services and consumer finance to private individuals, enterprises and institutions in Spain and Portugal. The main business units included in the Spain and Portugal area Spanish Retail Network, which manages individual customers, high net-worth individuals (private banking) and small companies and retailers in the Spanish market; Corporate and Business Banking, which manages business with small and medium enterprises (SMEs), large companies, institutions and developers in the Spanish market, and Other units, which includes consumer finance, that manages renting and leasing business, credit to individual and to enterprises for consumer products and Internet banking; European Insurance that manages the insurance business in Spain and Portugal, and BBVA Portugal, that manages the banking business in Portugal. The Spanish Retail Network unit services the financial and non-financial needs of households, professional practices, retailers and small businesses. The Corporate and Business Banking unit offers a range of services and products to SMEs, large companies, institutions and developers with specialized branch networks for each segment.

The Company�� European Insurance unit�� activities are conducted through! various insurance companies that provide direct insurance, reinsurance and insurance brokering services in Spain and Portugal and market products for different types of customers (private individuals, SMEs, retailers, professional service firms and providers and self-employed individuals) through this unit�� branch offices. BBVA Portugal manages its banking business in Portugal.

Wholesale Banking and Asset Management

The Wholesale Banking and Asset Management area focuses on providing services to large international companies and investment banking, capital markets and treasury management services to clients. The business units included in the Wholesale Banking and Asset Management area are Corporate and Investment Banking, which coordinates origination, distribution and management of a complete catalogue of corporate and investment banking products (corporate finance, structured finance, syndicated loans and debt capital markets) and provides global trade finance and global transaction services with coverage of large corporate customers specialized by sector (industry bankers); Global Markets, which handles the origination, structuring, distribution and risk management of market products, which are placed through its trading rooms in Europe, Asia and the Americas; Asset Management, which designs and manages the products that are marketed through its different branch networks including traditional asset management, alternative asset management and Valanza (its private equity unit); Industrial and Other Holdings, which helps to diversify the area�� businesses with the aim of creating medium and long-term value through active management of a portfolio of industrial holdings and other Spanish and international projects, and Asia.

During the year ended December 31, 2009, it launched two products: BBVA Bonos Cash (BBVA Cash Bonds), a money market fund for retail customers, and BBVA Bonos Largo Plazo Gobiernos II (BBVA Long-Term Government Bonds), a public-debt fu! nd. In ad! dition it launched through this unit additional fixed-income long-term funds, including BBVA Bonos Corporativos 2011 and BBVA Bonos 2014, which were sold to HNWI customers.

Mexico

The business units included in the Mexico area are Retail and Corporate banking and Pensions and Insurance. BBVA Bancomer launched six new mortgage products for lending to home buyers in 2009. These products included: loans for home improvements, remodeling or additions to homes and financial discount which provides liquidity to construction companies. In Mexico, it operates its pensions business through Afore Bancomer, its insurance business through Seguros Bancomer, its annuities business through Pensiones Bancomer and its health insurance business through Preventis.

The United States

The business units included in the United States area are BBVA Compass and Other units: BBVA Puerto Rico and Bancomer Transfers Services (BTS). During 2009 this unit marketed and sold several new products, The ClearPoints credit card, Business Build-to-order Checking, Compass for your Cause and Money Market Sweep.

South America

The South America business area includes its banking, insurance and pension businesses in South America. The business units included in the South America business area are Retail and Corporate Banking, which includes banks in Argentina, Chile, Colombia, Panama, Paraguay, Peru, Uruguay and Venezuela; Pension businesses, which includes pensions businesses in Argentina, Bolivia, Chile, Colombia, Ecuador and Peru and Dominican Republic, and Insurance businesses, which includes insurance businesses in Argentina, Chile, Colombia, Dominican Republic and Venezuela.

Corporate Activities

The Corporate Activities area handles its general management functions. These mainly consist of structural positions for interest rates associated with the euro balance sheet and exchange rates, together with liquidity management and shareholde! rs��fun! ds.

Advisors' Opinion:

• [By John Udovich]
  A.F.P Provida SA. A Chile-based company�involved in the management of private pension funds, A.F.P Provida SA�� activities include the investment and collection of its clients��contributions, the management of individual capitalization accounts and the provision of life and disability benefits, payments of funeral expenses and senior retirement pensions. A.F.P Provida SA also has operations through its subsidiaries in Peru, Ecuador and Mexico. Under former dictator Pinochet,�Chile privatized its otherwise bankrupted social security program�and mandates its citizens to invest a certain portion of their wages with government-endorsed asset management firms like A.F.P Provida SA. Right now, A.F.P Provida SA has a trailing P/E of 6.33 along with a forward dividend of $10.89 for a 12% dividend yield, but there is also a big catch. Back in February, it was reported that Metlife Inc (NYSE: MET) would acquire the firm from Banco Bilbao Vizcaya Argentaria SA (NYSE: BBVA) in a deal valued at about $2 billion in order to add fee income in Latin America���meaning that juicy dividend is no longer a sure bet for investors. On Monday, small cap A.F.P Provida SA rose 0.28% to $90.80 (PVD has 52 week trading range of $82.60 to $112.79 a share) for a market cap of $2.01 billion plus the stock is down 9.1% since the start of the year, up 2.3% over the past year and up 205.7% over the past five years.

• [By Lee Jackson]

  Banco Bilbao Vizcaya Argentaria S.A. (NYSE: BBVA) was raised to Outperform from Neutral by Credit Suisse.

  Caterpillar Inc. (NYSE: CAT) was started as Equal Weight at Morgan Stanley

Best Japanese Stocks To Invest In Right Now: CPFL Energia S.A.(CPL)

CPFL Energia S.A., through its subsidiaries, engages in the generation, distribution, and sale of electricity in Brazil. It generates electricity through hydroelectric, thermal, biomass, and wind power plants. The company also involves in the provision of energy commercialization, consultancy, and advisory services to agents in the energy sector; manufacture, commercialization, rental, and maintenance of electromechanical equipment; and provision of administrative services, as well as telephone answering services. It has an installed generating capacity of 2,309 MW. The company was founded in 1998 and is headquartered in Sao Paulo, Brazil.

Advisors' Opinion:

• [By Lisa Levin]

  Foreign Utilities: This industry rose 1.79% by 10:30 am ET. The top performer in this industry was CPFL Energia SA (NYSE: CPL), which gained 4.5%. CPFL Energia's trailing-twelve-month revenue is $6.13 billion.

• [By Selena Maranjian]

  Brazilian electricity giant CPFL Energia S.A. (NYSE: CPL  ) sank 20%, and recently yielded 5.9%. Its long-term debt has been rising, largely due to acquisitions, and its free cash flow has been shrinking (and even turning negative�recently). But it has been investing heavily in alternative energies, and it serves a massive and growing market in Brazil. The country's growth has been slower than many would like, but that won't last forever.

Best Japanese Stocks To Invest In Right Now: Forest Laboratories Inc (FRX)

Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company�� principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor (SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.

Aclidinium

In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback system which, through a ��olored control window��and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.

Linaclotide

Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.

Viibryd

As a result of its acquisition of Clinical Data, Inc. (Clinical Data) completed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.

Daliresp

In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.

Namenda

Namenda (memantine HCl) is an N-methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer�� disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer�� type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.

Bystolic

Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).

Savella

Savella (milnacipran HCl) is the Company�� selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.

Teflaro

In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.

Avibactam

Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.

Lexapro

Lexapro�� is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro�� (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.

Cariprazine

Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also undergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.

Levomilnacipran

Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.

GRT 6005

In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.

TTP399

In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.

Azimilide

In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA agreed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.

RGH-618

RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.

Advisors' Opinion:

• [By Sean Williams]

  Believe it or not, Forest Laboratories (NYSE: FRX  ) continued its string of good news following word from the Food and Drug Administration on Friday that Fetzima, a drug co-developed with Pierre Fabre Laboratories, had been approved to treat major depressive disorder. This is a big step for Forest Labs, which lost MDD drug Lexapro to patent expiration last year and now could be set to capitalize on a disease that can affect as many as 15 million people in the U.S. -- all with Eli Lilly's�Cymbalta, a $5 billion-a-year drug, set to lose patent protection itself in the fourth quarter.

• [By Jake L'Ecuyer]

  Leading and Lagging Sectors
  Tuesday morning, the healthcare sector proved to be a source of strength for the market. Healthcare stocks surged 1% in today's trading. Leading the sector was strength from Forest Laboratories (NYSE: FRX) and Chindex International (NASDAQ: CHDX) on acquisition news.

Best Japanese Stocks To Invest In Right Now: Universal Technical Institute Inc(UTI)

Universal Technical Institute, Inc. engages in the provision of postsecondary education for students seeking careers as professional automotive, diesel, collision repair, motorcycle, and marine technicians in the United States. It offers undergraduate degree, diploma, and certificate programs through its campuses under various brands, including Universal Technical Institute, Motorcycle Mechanics Institute and Marine Mechanics Institute, and NASCAR Technical Institute. The company also provides manufacturer-specific training programs comprising student paid electives at its campuses and manufacturer or dealer sponsored training at certain campuses and dedicated training centers. Universal Technical Institute, Inc. was founded in 1965 and is headquartered in Scottsdale, Arizona.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Universal Technical Institute (NYSE: UTI  ) , whose recent revenue and earnings are plotted below.

• [By Laura Brodbeck]

  Tuesday

  Earnings Expected From: Bank of Montreal (NYSE: BMO), United Natural Foods, Inc. (NASDAQ: UNFI), OmniVision Technology, Inc. (NASDAQ: OVTI), Universal Technical Institute, Inc. (NYSE: UTI) Economic Releases Expected: Chinese HSBC Services PMI, Australian GDP, Brazilian GDP, eurozone PPI, British construction PMI.

  Wednesday

• [By Eric Volkman]

  Universal Technical Institute (NYSE: UTI  ) doesn't seem like it needs to learn how to make dividend payments. The company is staying true to recent form by declaring a quarterly distribution, which is to be $0.10 per share. This will be paid on June 28 to shareholders of record as of June 21. That amount matches each of the firm's previous regular distributions, the most recent of which was disbursed in late March.